Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT06734871Phase 1Recruiting
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-1190B in B-cell non-Hodgkin lymphoma. Primary endpoints: Adverse Events (AE) after CT1190B infusion at 12 months and Maximum Tolerated Dose and/or dose range at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
CT-1190B
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06734871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734871.